

Amendments to the Claims

1. (Currently Amended) ~~The use of~~ A method of using 17- β estradiol or a new derivative thereof for improving reendothelization and vascular endothelial function in a patient in the making of a medication or a device comprising for in-situ administration administering 17- β estradiol or a derivative thereof at the injured site in the lumen of a blood vessel having suffered vascular injury, at the injured site, for improving reendothelization and vascular endothelial function in a patient.
2. (Currently Amended) ~~The use~~ A method as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 1 to 5000 $\mu\text{g/Kg}$ of patient's body weight.
3. (Currently Amended) ~~The use~~ A method as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 50 $\mu\text{g/Kg}$ of patient's body weight.
4. (Currently Amended) ~~The use~~ A method as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 30 $\mu\text{g/Kg}$ of patient's body weight.
5. (Currently Amended) ~~The use~~ A method as defined in claim 1, further comprising a pharmaceutically acceptable carrier wherein said pharmaceutically acceptable carrier comprises hydroxypropyl-beta-cyclodextrin (HPCD).
6. (Currently Amended) ~~The use~~ A method as defined in claim 5, wherein HPCD is present in a dose capable of solubilizing 17- β estradiol or a derivative thereof.
7. (Currently Amended) ~~The use~~ A method as defined in claim 4, ~~where~~ wherein said 17- β estradiol or a derivative thereof is admixed with a carrier comprising at least 0.63 mg hydroxypropyl-beta-cyclodextrin per kilogram of patient's body weight.
8. (Currently Amended) ~~The use~~ A method as defined in claim 1, which ~~is for~~ comprises a single administration.

9. (New) A method as defined in claim 1, wherein said 17- β estradiol or a derivative thereof is administered with a device.
10. (New) A method as defined in claim 9, wherein the device is a catheter containing said 17- β estradiol or a derivative thereof and a pharmaceutically acceptable carrier.
11. (New) A method as defined in claim 9, wherein the device is a stent coated with said 17- β estradiol or a derivative thereof and a pharmaceutically acceptable carrier.
12. (New) A method as defined in claim 1, wherein said 17- β estradiol or a derivative thereof is administered following percutaneous transluminal coronary angioplasty (PTCA).
13. (New) A method as defined in claim 1, wherein said 17- β estradiol or a derivative thereof is administered simultaneously with percutaneous transluminal coronary angioplasty (PTCA).
14. (New) A method as defined in claim 1, wherein said method uses 17- β estradiol.
15. (New) A method as defined in claim 14, wherein 17- β estradiol is present in a dose unit of 1 to 5000 $\mu\text{g/Kg}$ of patient's body weight.
16. (New) A method as defined in claim 14, wherein 17- β estradiol is present in a dose unit of 10 to 50 $\mu\text{g/Kg}$ of patient's body weight.
17. (New) A method as defined in claim 14, wherein 17- β estradiol is present in a dose unit of 10 to 30 $\mu\text{g/Kg}$ of patient's body weight.
18. (New) A method as defined in claim 14, which comprises a single administration.
19. (New) A method as defined in claim 14, wherein 17- β estradiol is administered with a device.

20. (New) A method as defined in claim 19, wherein the device is a catheter containing 17- β estradiol and a pharmaceutically acceptable carrier.
21. (New) A method as defined in claim 19, wherein the device is a stent coated with 17- β estradiol and a pharmaceutically acceptable carrier.
22. (New) A method as defined in claim 14, wherein 17- β estradiol is administered following percutaneous transluminal coronary angioplasty (PTCA).
23. (New) A method as defined in claim 14, wherein 17- β estradiol is administered simultaneously with percutaneous transluminal coronary angioplasty (PTCA).